New migraine治疗 drug Erenumab could cut attacks in half
UK researchers report Erenumab as a monthly preventative reduces migraine days by about 3.7 from 8.3 per month, vs 1.8 with placebo, in a 955 patient NEJM study. The drug targets calcitonin gene related peptide, with phase III results submitted to EMA and FDA for approval. if approved it could transform life for about half a million sufferers.
MENTIONED IN THIS ARTICLE
Peter Goadsby
King’s College London
New England Journal of Medicine
European Medicines Agency
FDA
U.S
Novartis
Amgen
Canada
Nejm.org
Safer Choices?: Facial Injuries Rising in Seniors
Wayne State University analysis of five years of ER data shows 20 500 adults aged 55 and older Sustaining facial fractures with a 45 percent rise over prior five years. Cycling and team sports account for most injuries. walking pets and gardening also contribute.
MENTIONED IN THIS ARTICLE
JAMA
Wayne State University
Detroit
Also Mentioned on This Page
Gillian Slade
Toronto
Wayne State
Docgiff.com
Docgiff
Dr. Gifford Jones
Doctor Game
POWER
Ibabiesor
Visa
Mastercard
Medicine Hat News
Dunmore Rd
Medhatclass
Gmail
Amedicine
Har News